Navigation Links
Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
Date:11/19/2012

BETHESDA, Md., Nov. 19, 2012 /PRNewswire-USNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

Under the new six-year pre-clinical research program with Pfizer, CFFT will invest up to $58 million to speed the discovery and development of potential therapies that target the underlying cause of cystic fibrosis. The program's goal is to advance one or more drug candidates into the clinic by the end of the multiyear collaboration.

"We are excited to expand our efforts with Pfizer to accelerate the development of more therapies that treat the root cause of CF and benefit the greatest number of people with the disease," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. "Pfizer brings impressive technical and scientific expertise, along with its commitment to improving the lives of people with cystic fibrosis."

In people with the Delta F508 mutation, a defective protein called CFTR does not fold correctly and is unable to reach the cell surface, where it is needed to help maintain the proper flow of salt and fluids into the airways. As a result, thick secretions form in the airways, leading to serious lung infections and lung damage. Nearly 90 percent of people with CF have at least one copy of the Delta F508 mutation. 

The collaboration will focus on identifying therapies that help restore normal function of the defective protein. Pfizer researchers will draw on their leading expertise in developing therapies that help mutated proteins fold and route correctly within the cell.

"Innovative collaborations between industry and patient organizations are increasingly critical in expe
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
2. FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
3. OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
4. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
6. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure
11. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  Neurocrine Biosciences, Inc. (NASDAQ: ... has joined the company as Vice President, Medical ... welcome Dr. Bill Aurora to the Neurocrine ... Kevin Gorman , President and Chief Executive Officer of ... exchange and outreach coupled with his extensive network and ...
(Date:5/4/2015)... May 4, 2015  Amgen (NASDAQ: AMGN ) will ... 8 a.m. ET on Thursday, May 7, 2015, at the ... Hooper , executive vice president of Global Commercial Operations at ... presentation can be accessed from the Events Calendar on Amgen,s ... webcast will also be available on Amgen,s website for 90 ...
(Date:5/4/2015)... , May 4, 2015 DePuy Synthes CMF* ... Repair, the first commercially available biosynthesized dural replacement derived ... is a part of the DePuy Synthes Companies of ... tissue membrane that covers and protects the brain and ... to allow surgeons to access the brain. A dural ...
Breaking Medicine Technology:Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 2Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 3Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... YORK, Jan. 10, 2011 Resolvyx Pharmaceuticals ( Resolvyx ... ), a successor firm to Celtic Pharma, announced today ... which Celtic Therapeutics has acquired and licensed worldwide rights ... treatment of dry eye syndrome and other ophthalmic conditions. ...
... 2011 Astellas Pharma Inc. (TSE: 4503) ... to conduct, in conjunction with executive management, a review of ... Prosidion was acquired as part of Astellas, acquisition of OSI ... two drug candidates in development for diabetes and obesity, as ...
Cached Medicine Technology:Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 2Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 3Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 4Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary 2Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary 3
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 ... insurance programs, announces the expansion of coverage for its ... a leading provider of industry-tailored insurance and proactive risk ... & Company, we are dedicated to providing our customers ... meet their many evolving needs. We are excited to ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... May 04, 2015 Now in its ... clinical leaders who have made outstanding contributions to the ... serve, both in acute and post-acute care settings. The ... Post-Acute Provider of the Year, Advanced Practice Clinician of ... Provider of the Year. Recipients are selected by IPC’s ...
(Date:5/4/2015)... May 04, 2015 Los Angeles ... offering a more comfortable and attractive alternative for patients ... choice for those who have lost teeth. Unfortunately, they ... insecure or slip at the worst possible moment and ... talks. They can also painfully pinch or rub gums, ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
... , , WAYNE, Pa., July ... documentation software, workflow tools, consulting and staffing services has announced ... Marketing and Communications. Reporting directly to founder and CEO ... marketing initiatives that blend the strong brand of Precyse,s services ...
... , BATESVILLE, Ind., July 29 Hillenbrand, Inc. (NYSE: ... the market opens Wednesday, Aug. 12, 2009. The full text of ... site at www.HillenbrandInc.com . , , ... with investors and financial analysts the same day at 8 a.m. ...
... , CARLSBAD, Calif., July ... announced today that Cardiac Science Corporation has purchased a ... Group. Cardiac Science develops, manufactures, and markets ... and Holter systems, cardiac rehabilitation telemetry, and data management ...
... , , DARIEN, Conn., July 29 ... The Switch , a sparkling 100% juice, is expanding its availability ... Amazon.com, The Switch has added key retailers Tops, ... months. And the list of eager retailers keeps growing with Wegmans, ...
... , , CARMEL, Ind., ... announced that Christopher J. Foote has been promoted to vice president, ... in 1999 and served previously as senior managing actuary for asset-liability ... and shared actuarial services. , , ...
... , SAN DIEGO, July 29 ... solutions that can reach over 3.5 billion mobile phones globally, today announced ... industry leaders. , , Key Facts: , ... the 7-member advisory board is to provide Globaltel Media,s executive management team ...
Cached Medicine News:Health News:Precyse Solutions Taps Former Siemens Executive to Lead New Marketing Organization 2Health News:Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call 2Health News:Patriot Scientific Corporation Announces Cardiac Science Corporation's Purchase of a Moore Microprocessor Patent(TM) Portfolio License 2Health News:People Across the Country are Making The Switch! 2Health News:Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board 2Health News:Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board 3
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
True hemostasis management is achieved with the Hepcon HMS PLUS Hemostasis Management System from Medtronic. This multi-purpose, intuitive system easily performs in-vitro diagnostic procedures....
An Innovative New System to Help You Meet the Challenges of Anterior Spine Surgery...
Medicine Products: